HealthDay News — For lung transplant (LTx) recipients, prolonged exposure to voriconazole may be associated with the development or recurrence of skin squamous cell carcinoma (SCC), according to a study published online in the Journal of Pharmacy Practice and Research.
Chin Fen Neoh, PhD, from the Universiti Teknologi MARA in Bandar Puncak Alam, Malaysia, and colleagues conducted a retrospective cohort study to describe the extent and outcomes of new and recurrent SCC in 102 adult LTx recipients with skin SCC who had received voriconazole.
The researchers found that 13.7% of the LTx patients had at least 1 episode of skin SCC. Group 1 (7 patients) had SCC during or after voriconazole exposure; Group 2 (3 patients) had skin SCC before initiation of voriconazole therapy, which subsequently recurred or worsened; Group 3 (3 patients) had a history of skin SCC before voriconazole exposure but no skin SCC during treatment; and Group 4 (1 patient) had multiple skin SCCs before LTx and voriconazole use and developed further SCC after voriconazole use. In Groups 1, 2, and 3, the median of voriconazole exposure was 119, 1,127, and 173 days, respectively. In 3 and 8 patients, respectively, there was a probable and possible correlation between voriconazole exposure and skin SCC.
“Prolonged voriconazole exposure may contribute to the development, recurrence, and progression of skin SCC in LTx patients,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Neoh CF, Snell GI, Levvey B, et al. Squamous cell carcinoma of the skin and voriconazole therapy in lung transplant recipients: a case series. J Clin Pharm Pract Res. 2017;47(3):228-235. doi:10.1002/jppr.1234